搜索
产品
社区
市场
新闻
经纪商
更多
CN
开始
trade it to $30
Alector, Inc.
(
NASDAQ:ALEC
)
KhanhC.Hoang
NASDAQ:ALEC
Alector, Inc.
Fibonacci
1
0
fibonacci
The safety data is favorable and biomarker/clinical data of AL001 (latozinemab) is supportive of activity in this expanded group of patients. Today's data also suggests the potential for a treatment effect in other TDP pathologies (such as ALS).
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款
阅读更多信息。